Exhibit
10.19


 


INTELLECTUAL
PROPERTY SECURITY AGREEMENT


 


This
Intellectual Property Security Agreement (“IP Security Agreement”) dated as of March 2, 2022, is made and entered
into by and among Curative Biotechnology, Inc., a Florida corporation (the “Company”), any subsidiary of the Company
that is a signatory hereto either now joined or joined in the future (such subsidiaries, together with the Company, the “Debtors”),
and Puritan Partners LLC, as Holder of the 12.5% Senior Secured Notes due March 2, 2023 in aggregate principal amount of $1,142,857.14
(the “Notes”) of the Company.


 


WHEREAS,
the Company has entered into a Securities Purchase Agreement, dated as of the date hereof and as may be amended from time to time (the
“Securities Purchase Agreement”), [_____] (the “Lender”), and the Company, and the Lender has entered
into a Security Agreement dated as of the date hereof and as may be amended from time to time (the “Security Agreement”);


 


WHEREAS,
the Lender has purchased or will purchase from the Company, among other things, the Note pursuant to the provisions of the Securities
Purchase Agreement; and


 


WHEREAS,
under the terms of the Securities Purchase Agreement and the Security Agreement, the Company and the other Debtors have granted to Lender
a first priority security interest in, among other Collateral, all Intellectual Property of the Debtors, and the Company has agreed as
a condition thereof to execute this IP Security Agreement for recording with the United States Patent and Trademark Office, the United
States Copyright and other governmental authorities.


 


NOW,
THEREFORE, for good and valuable consideration, both the receipt and sufficiency of which are hereby acknowledged, the Debtors hereby
agrees as follows:


 


SECTION
1. Definitions. Any term not defined herein will have the definition ascribed to it in the Securities Purchase Agreement, Security
Agreement or Note. The following terms have the meanings set forth below:


 


(a)
“Copyrights” means all of the following to the extent now owned or hereafter
adopted or acquired by any of the Debtors: (i) all copyrights (whether statutory or common law, whether established or registered in
the United States or any other country or political subdivision thereof, whether registered or unregistered and whether published or
unpublished), rights and interests in copyrights, works protectable by copyright, and General Intangibles of like nature, all registrations
and recordings thereof, and all applications in connection therewith, including all registrations, recordings, and applications in the
United States Copyright Office or in any similar office or agency of the United States, any state or territory thereof, or any other
country or any political subdivision thereof and all research and development relating to the foregoing, (ii) all reissues, extensions,
continuations, and renewals thereof and amendments thereto, (iii) income, fees, royalties, damages, claims, and payments now or hereafter
due and/or payable with respect thereto, including damages and payments for past, present and future infringements thereof, (iv) rights
corresponding thereto throughout the world and (v) rights to sue for past, present, and future infringements thereof.


 


(b)
“Copyright License” means any and all rights to the extent now owned or
hereafter acquired by Debtors under any written or oral agreement granting any right to use any Copyright or Copyright registration,
in each case to the extent assignable by any of the Debtors; provided, that, the Company has identified on Schedule C attached
hereto whether or not any of the Debtors’ Copyrights or Copyright registrations are not assignable.


 




    	 



     


    

 


(c)
“Patents” shall mean one or all of the following, to the extent now or hereafter
owned by any of the Debtors or in which any of the Debtors now has or hereafter acquires any rights: (i) all letters patent of the United
States or any other country, all registrations, and recordings thereof, and all applications for letters patent of the United States
or any other country, (ii) all reissues, continuations, continuations-in-part, divisions, reexaminations, or extensions of any of the
foregoing and (iii) all inventions disclosed in and claimed in the Patents and any and all trade secrets and know-how related thereto.


 


(d)
“Patent License” shall mean all of the following to the extent now owned
or hereafter acquired by any of the Debtors or in which any of the Debtors now has or hereafter acquires any rights: to the extent assignable
or transferable by any Debtor, any written agreement granting any right to make, use, sell, and/or practice any invention or discovery
that is the subject matter of a Patent, in each case to the extent assignable or transferable, without third party consent, by any Debtor;
provided, that, the Company has identified on Schedule A attached hereto those Patents Licenses that are not assignable or transferable
without third party consent.


 


(e)
“Trademarks” shall mean one or all of the following, to the extent now owned
or hereafter acquired by any of the Debtors or in which any of the Debtors now has or hereafter acquires any rights: (i) all trademarks
(whether registered or unregistered), trade names, corporate names, business names, trade styles, service marks, logos, other source
or business identifiers, prints, and labels on which any of the foregoing have appeared or appear, designs and general intangibles of
like nature, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and all applications in connection
therewith, including, without limitation, registrations, recordings, and applications in the United States Patent and Trademark Office
or in any similar office or agency of any State of the United States or any other country or any political subdivision thereof, (ii)
all reissues, extensions, or renewals thereof and (iii) the goodwill associated with or symbolized by any of the foregoing.


 


(f)
“Trademark License” shall mean all of the following, to the extent now owned
or hereafter acquired by any of the Debtors or in which any of the Debtors now has or hereafter acquires any rights: any written agreement
granting any right to use any Trademark or Trademark registration, in each case to the extent assignable or transferable, without third
party consent, by any Debtor; provided, that, the Company has identified on Schedule B attached hereto those Trademarks or Trademark
registrations that are not assignable without third party consent.


 


SECTION
2. Grant of Security. Each of the Debtors hereby grants to Lender, a first priority security interest in all of such Debtor’s
right, title, and interest in and to the following (the “Collateral”):


 


	 	(i)	all
    of its Patents and all Patent Licenses to which it is a party, including, but not limited to, those set forth on Schedule A hereto,
    subject to the third party’s right to terminate such Patents or Patent Licenses in the event of assignment, transfer or encumbrance
    set forth on Schedule A; 
	 	 	 
	 	(ii)	all
    of its Trademarks and all Trademark Licenses to which it is a party, including, but not limited to, those set forth on Schedule
    B hereto, together with all goodwill of the business connected with the use of, and symbolized by, each Trademark and each Trademark
    License, subject to the third party’s right to terminate such Trademarks or Trademark Licenses in the event of assignment,
    transfer or encumbrance set forth on Schedule B; 
	 	 	 
	 	(iii)	all
    of its Copyrights and all Copyright Licenses to which it is a party, including, but not limited to, those set forth on Schedule
    C hereto, subject to the third party’s right to terminate such Copyrights or Copyright Licenses in the event of assignment,
    transfer or encumbrance as set forth on Schedule C;


 




    	 



     


    

 


	 	(iv)	all
    reissues, divisions, continuations, continuations-in-part, extensions, renewals, and reexaminations of any of the foregoing, all
    rights in the foregoing provided by international treaties or conventions, all rights corresponding thereto throughout the world
    and all other rights of any kind whatsoever of the Debtors accruing thereunder or pertaining thereto; 
	 	 	 
	 	(v)	any
    and all of Debtor’s claims for damages and injunctive relief for past, present, and future infringement, dilution, misappropriation,
    violation, misuse, breach, or injury with respect to any of the foregoing, with the right, but not the obligation, to sue for and
    collect, or otherwise recover, such damages; and 
	 	 	 
	 	(vi)
    	any
    and all products and proceeds of, collateral for, income, royalties, and other payments now or hereafter due and payable with respect
    to, and supporting obligations relating to, any and all of the Collateral of or arising from any of the foregoing. Except as may
    be set forth on Schedule D hereto, and subject to the third party’s right of termination upon assignment, transfer or
    encumbrance set forth on Schedule D, the Debtor is the sole owner of the Collateral, free and clear of any liens, security
    interests, encumbrances, rights or claims, and is fully authorized to grant the first priority security interest in the Collateral.
    To the best of Debtor’s knowledge after due inquiry, except as set forth on Schedule D hereto, there is not on file
    in any governmental or regulatory authority, agency or recording office an effective financing statement, security agreement, license
    or transfer or any notice of any of the foregoing relating to Debtor (other than those that will be filed in favor of the Secured
    Party pursuant to this Agreement) covering or affecting the Collateral. So long as this Agreement shall be in effect, the Debtor
    shall not execute and shall not knowingly permit to be on file in any such office or agency any such financing statement or other
    document or instrument (except to the extent filed or recorded as of the date hereof or in favor of the Secured Party pursuant to
    the terms of this Agreement).


 


Notwithstanding
the foregoing, nothing herein shall be deemed to constitute an assignment of any asset which, in the event of an assignment, becomes
void by operation of applicable law or by its terms or the assignment of which is otherwise prohibited by applicable law or by its terms
(in each case to the extent that such applicable law is not overridden by Sections 9-406, 9-407 and/or 9-408 of the UCC or other similar
applicable law); provided, however, that, to the extent permitted by applicable law, this Agreement shall create a valid security interest
in such asset and, to the extent permitted by applicable law, this IP Security Agreement shall create a valid security interest in the
proceeds of such asset.


 


SECTION
3. Security for Obligations. The grant of a first priority security interest, subject to the third party’s right to terminate
in the event of an assignment, transfer or encumbrance set forth on any of the Schedules hereto, in the Collateral by the Debtors under
this IP Security Agreement secures the prompt and complete payment and performance when due of all of the Obligations, whether direct
or indirect, now existing or hereafter arising, absolute or contingent, and whether for principal, reimbursement obligations, interest,
premiums, penalties, fees, guarantee obligations, indemnifications, contract causes of action, costs, expenses, or otherwise.


 


SECTION
4. Recordation. Each of the Debtors authorizes and requests that the Register of Copyrights, the Commissioner for Patents, the
Commissioner for Trademarks and any other applicable governmental authority record this IP Security Agreement.


 




    	 



     


    

 


SECTION
5. Grants, Rights and Remedies. This IP Security Agreement has been entered into in conjunction with the provisions of the Securities
Purchase Agreement and the Security Agreement. Each Debtor does hereby acknowledge and confirm that the grant of the first priority security
interest, subject to the third party’s right to terminate in the event of an assignment, transfer or encumbrance set forth on any
of the Schedules hereto, hereunder and the rights and remedies of, Lender with respect to the Collateral are more fully set forth in
the Security Agreement, the terms and provisions of which are incorporated herein by reference as if fully set forth herein.


 


SECTION
6. Future Acquisitions. The Company represents and warrants that Schedules A, B and C attached hereto set forth any and all intellectual
property rights in connection to which the Company has registered or filed an application with either the United States Patent and Trademark
Office or the United States Copyright Office, as applicable. The Company shall give the Lender prior written notice of no less than five
(5) Business Days before filing any additional application for registration of any trademark and prompt notice in writing of any additional
trademark registrations, patent registration, or copyright registrations granted therefor after the date hereof. Without limiting the
Company’s obligations under this paragraph, each of the Debtors hereby authorizes the Lender unilaterally to modify this IP Security
Agreement by amending Schedules A, B, C or D to include any future patents, trademarks, copyrights, licenses thereto or applications
therefor of any Debtor. Notwithstanding the foregoing, no failure to so modify this IP Security Agreement or amend Schedules A, B, C
or D shall in any way affect, invalidate or detract from Lender’s first priority security interest in all Collateral, whether or
not listed on Schedule A, B, C or D.


 


SECTION
7. Remedies. If there occurs an Event of Default, the Lender shall be entitled to exercise any and all remedies available to the
Secured Lender under the Security Agreement for the benefit of Lender.


 


SECTION
8. Term of Agreement. This IP Security Agreement shall terminate on the date on which all payments under the Notes have been indefeasibly
paid in full. Upon termination of this IP Security Agreement, the Lender shall promptly execute such documents or instruments and take
such further actions as the Company or any Debtor may reasonably request for the purposes of releasing the security interests granted
herein. Debtor may file any terminations with any applicable office upon such termination date.


 


SECTION
9. Miscellaneous. Section 19 of the Security Agreement is hereby incorporated herein by reference as if fully set forth herein,
mutatis mutandis.


 


SECTION
10. Governing Law. This IP Security Agreement shall be governed by, and construed and interpreted in accordance with the internal
laws of the State of New York, without giving effect to its choice of law provisions that would require the application of another state’s
laws.


 


SECTION
11. Execution in Counterparts. This IP Security Agreement may be executed in any number of counterparts, each of which when so
executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement


 




    	 



     


    

 


IN
WITNESS WHEREOF, each Debtor has caused this IP Security Agreement to be duly executed and delivered by its officer thereunto duly authorized
as of the date first above written.


 





	CURATIVE BIOTECHNOLOGY, INC., AS DEBTOR	 
	 	 
	BY:	 /s/
    Richard Garr 	 
	Richard Garr 	 
	CEO 	 
	 	 	 
	PURITAN PARTNERS LLC, AS LENDER 	 
	 	 
	BY:	 /s/ Richard Smithline 	 
	 	Richard Smithline	 
	 	Managing Member	 


 




    	 



     


    

 


SCHEDULE
A


PATENTS
AND PATENT LICENSES


 




    	 



     


    

 


SCHEDULE
B


TRADEMARKS
AND TRADEMARK LICENSES


 




    	 



     


    

 


SCHEDULE
C


COPYRIGHTS
AND COPYRIGHT LICENSES


 




    	 



     


    

 


SCHEDULE
D


EXISTING
LIENS ON COLLATERAL